Tarvacin Equivalent Inhibits Tumor Growth by up to 90 Percent

Peregrine Pharmaceuticals has announced the publication of data in Clinical Cancer Research demonstrating significant antitumor activity in various tumor models using the murine monoclonal antibody 3G4, an equivalent of the company's Tarvacin, that recognizes anionic phospholipids exposed on the surface of tumor blood vessels.

These studies were performed by researchers at University of Texas Southwestern Medical Center at Dallas. The article stated that treatment with 3G4 as a monotherapy inhibited the growth of various different tumors in mice. It reduced the growth by up to 75 percent in established human breast tumor models, up to 90 percent in a mouse fibrosarcoma model, and 50 percent in a human Hodgkin's tumor model.